The new firm is based in Burlington, VT, and was founded by CEO Christian Cobaugh, who has previously worked on mRNA development at Omega Therapeutics, Translate Bio, Arcturus Therapeutics, and Alexion Pharmaceuticals. It plans to use the funding for its technical development and commercial operations.

Vernal currently offers manufacturing-research-use mRNA and is scaling its manufacturing process that will become an advanced staging ground for clinical manufacturing projects, it said.

Sanofi to invest $474M annually on mRNA vaccine R&D
Sanofi will spend approximately 400 million euros ($474 million U.S.) to accelerate the research and development (R&D) of messenger RNA (mRNA)...

Samsung Biologics readies mRNA vaccine drug substance production
Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.

New research uncovers how SARS-CoV-2 hijacks RNA host proteins
A new study has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell proteins, many of which are fundamental for infection. The...

Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.

BrickBio expands antibody-drug conjugate programs
BrickBio said it has received positive data on its first clinical novel antibody-drug conjugate candidate for treating breast cancer and gastric cancer.